<HTML>
<HEAD>
<TITLE>    S-8
</TITLE>
</HEAD>
<BODY>



<P ALIGN=CENTER><B> As filed with the Securities and Exchange Commission on December 21,
2000</B></P>
<P ALIGN=RIGHT><B> Registration Statement No. 333- </B> </P>

<HR SIZE=2 NOSHADE>
<P ALIGN=CENTER><B> SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P ALIGN=CENTER><FONT SIZE=3><B>FORM S-8<BR>
REGISTRATION STATEMENT UNDER<BR>
THE SECURITIES ACT OF 1933</B></FONT></P>

<P ALIGN=CENTER><B>ALLIANCE PHARMACEUTICAL CORP.</B><BR>
<FONT SIZE=3>(Exact name of registrant as specified in its charter)</FONT></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20% ALIGN=CENTER>
<TD WIDTH=30% ALIGN=CENTER> <FONT SIZE=1><B>New York</B><BR>
                                  (State or other jurisdiction<BR>
                              of incorporation or organization)</FONT></TD>
<TD WIDTH=30% ALIGN=CENTER> <FONT SIZE=1><B>14-1644018</B><BR>
                            (I.R.S. Employer<BR>
                           Identification Number)
                           </FONT></TD>
<TD WIDTH=20% ALIGN=CENTER>
</TR>
</TABLE>


<P ALIGN=CENTER><FONT SIZE=3><B>3040 Science Park Road<BR>
San Diego, CA 92121<BR>
(858) 410-5200</B></FONT></P>
<P><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Address,
including zip code, and telephone number, including area code of
registrant&#146;s principal executive offices) </FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>2000 STOCK OPTION PLAN OF ALLIANCE PHARMACEUTICAL CORP.</B></FONT><BR>
<FONT SIZE=1>(Full title of the plan)</FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>DUANE J. ROTH<BR>
Chief Executive Officer<BR>
Alliance Pharmaceutical Corp.<BR>
3040 Science Park Road<BR>
San Diego, CA 92121<BR>
(858)410-5200</B></FONT><BR>
<FONT SIZE=1>(Name, address, including zip code, and telephone number, of agent
for service of process)</FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>Copy to:</B><BR>
Melvin Epstein, Esq.<BR>
Stroock &amp; Stroock &amp; Lavan LLP<BR>
180 Maiden Lane<BR>
New York, NY 10038</FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>CALCULATION OF REGISTRATION FEE</B></FONT></P>

<PRE>
<FONT SIZE=1>
---------------------------------------------------------------------------------------------------------------------------
                                                    Proposed Maximum      Proposed Maximum Aggregate   Amount of
 Title of Shares             Amount to be           Aggregate Price       Offering Price               Registration Fee
 to be Registered            Registered             Per Unit (1)
---------------------------------------------------------------------------------------------------------------------------
 Common Stock, $.01 par
         value.              2,100,000 shares (2)     $8.19 per share      $17,199,000                 $4,540.54
---------------------------------------------------------------------------------------------------------------------------


(1) Estimated solely for the purpose of calculating the registration fee
    pursuant to Rule 457(c) and (h) of the Securities Act of 1933, as amended, based
    on the average of the high and low prices of the common stock on the Nasdaq
    National Market on December 19, 2000.

(2) Pursuant to Rule 416(a) under the Securities Act of 1933, this Registration
    Statement also covers an indeterminate number of shares of Common Stock which
    may be issued by reason of stock splits, stock dividends or similar
    transactions.
</FONT>
</PRE>

<P ALIGN=LEFT><FONT SIZE=3><B>PART I</B></FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
documents containing the information specified in Part I of Form S-8 will be
sent or given to employees as specified by Rule 428(b)(1) promulgated under the
Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Such
documents need not be filed with the Securities and Exchange Commission (the
&#147;Commission&#148;) either as part of this Registration Statement or as
prospectuses or prospectus supplements pursuant to Rule 424 under the Securities
Act. These documents and the documents incorporated by reference in the
Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken
together, constitute a prospectus that meets the requirements of Section 10(a)
of the Securities Act. See Rule 428(a)(1) under the Securities Act. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Registration Statement covers 2,100,000 shares of Alliance Pharmaceutical Corp.
(the &#147;Registrant&#148;) Common Stock, $.01 par value (plus any additional
shares of Common Stock that may be issued by reason of stock splits, stock
dividends or similar transactions), to be issued pursuant to the
Registrant&#146;s 2000 Stock Option Plan. </FONT></P>

<P ALIGN=LEFT><FONT SIZE=3><B>PART II</B></FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></FONT></P>

<P ALIGN=LEFT><FONT SIZE=3><B>Item 3. Incorporation of Documents by Reference.</B></FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following documents filed by the Registrant with the Securities and Exchange
Commission (the &#147;Commission&#148;) are incorporated herein by reference: </FONT></P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant's Annual Report on Form 10-K for
the fiscal year ended June 30, 2000;</P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Registrant's Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2000;</P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All other reports filed by the Registrant pursuant to Sections 13(a) and 15(d)
of the Exchange Act since the fiscal year covered by the annual report referred
to in (a) above; and </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The description of the Registrant&#146;s Common Stock, $.01 par value, which is
contained in the Registrant&#146;s Registration Statement on Form&#160;8-A,
declared effective October 25, 1984, filed with the Commission to register such
Common Stock pursuant to Section 12(b) of the Securities Exchange Act of 1934,
as amended (the &#147;Exchange Act&#148;). </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
documents subsequently filed by the Registrant pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective
amendment which indicates that all securities offered hereby have been sold or
which deregisters all securities then remaining unsold, shall be deemed to be
incorporated by reference herein and to be a part hereof from the date of filing
of such documents. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
statement contained herein or in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Registration Statement to the extent that a statement
contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference herein modifies or supersedes such
statement. Any statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this Registration
Statement. </FONT></P>

<P ALIGN=LEFT><FONT SIZE=3><B>Item 4. <U>Description of Securities.</U></B></FONT></P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not
Applicable.</P>



<P ALIGN=LEFT><FONT SIZE=3><B>Item 5.  <U>Interests of Named Experts and Counsel</U>.</B></FONT></P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not
Applicable.</P>


<P ALIGN=LEFT><FONT SIZE=3><B>Item 6. <U>Indemnification of Directors and Officers</U>.</B></FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Certificate of Incorporation and By-laws of the Registrant provide for the
Registrant to indemnify its officers, directors and employees to the fullest
extent permitted by the New York Corporation Law against certain liabilities and
expenses. </FONT></P>

<P ALIGN=LEFT><FONT SIZE=3><B>Item 7. <U>Exemption From Registration Claimed</U>.</B></FONT></P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not
Applicable.</P>

<P ALIGN=LEFT><FONT SIZE=3><B>Item 8. <U>Exhibits</U>.</B></FONT></P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10% ALIGN=LEFT></TD>
<TD WIDTH=15% ALIGN=LEFT>Exhibit<BR>
<U>Number</U></TD>
<TD WIDTH=75% ALIGN=LEFT><u>Description</U></TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10% ALIGN=LEFT></TD>
<TD WIDTH=15% ALIGN=LEFT>4.1</TD>
<TD WIDTH=75% ALIGN=LEFT>Option Plan</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10% ALIGN=LEFT></TD>
<TD WIDTH=15% ALIGN=LEFT>4.2</TD>
<TD WIDTH=75% ALIGN=LEFT>
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 of
the Registrant's Form S-2 dated April 19, 1989).
</TD>
</TR>
</TABLE>
<BR>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10% ALIGN=LEFT></TD>
<TD WIDTH=15% ALIGN=LEFT>5</TD>
<TD WIDTH=75% ALIGN=LEFT>Opinion of Stroock &amp; Stroock &amp; Lavan LLP.</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10% ALIGN=LEFT></TD>
<TD WIDTH=15% ALIGN=LEFT>23.1</TD>
<TD WIDTH=75% ALIGN=LEFT>Consent of Stroock &amp; Stroock &amp; Lavan LLP (included in Exhibit 5 hereto).</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10% ALIGN=LEFT></TD>
<TD WIDTH=15% ALIGN=LEFT>23.2</TD>
<TD WIDTH=75% ALIGN=LEFT>Consent of Ernst &amp; Young LLP, Independent Auditors.</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10% ALIGN=LEFT></TD>
<TD WIDTH=15% ALIGN=LEFT>24</TD>
<TD WIDTH=75% ALIGN=LEFT>Power of Attorney (included as part of the signature page of this Registration
Statement).
</TD>
</TR>
</TABLE>
<BR>


<P ALIGN=LEFT><FONT SIZE=3><B>Item 9. <U>Undertakings</U>.</B></FONT></P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The undersigned
Registrant hereby undertakes:</P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement: </FONT></P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=10%>&nbsp;</TD>
<TD WIDTH=90%><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of
1933;</FONT>
</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=10%>&nbsp;</TD>
<TD WIDTH=90%><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)
To reflect in the prospectus any facts or events arising after the effective
date of the Registration Statement (or the most recent post- effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the Registration Statement;</FONT>
 </TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD WIDTH=10%>&nbsp;</TD>
<TD WIDTH=90%><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)
To include any material information with respect to the plan of distribution not
previously disclosed in the Registration Statement or any material change to
such information in the Registration Statement; </FONT>
</TD>
</TR>
</TABLE>
<BR>

<P><FONT SIZE=3><I>provided, however</I>,
that paragraphs (1)(i) and (1)(ii) do not apply if the Registration Statement is
on Form S-3 or Form S-8 and the information required to be included in a
post-effective amendment by those paragraphs is contained in periodic reports
filed with or furnished to the Commission by the Registrant pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by
reference in the Registration Statement. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new Registration Statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial <I>bona fide</I> offering thereof. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the
offering. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Registrant is a foreign private issuer, to file a post-effective
amendment to the Registration Statement to include any financial statements
required by Rule 3-19 of Regulation S-X at the start of any delayed offering or
throughout a continuous offering. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the Registrant&#146;s
annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act
of 1934 (and, where applicable, each filing of an employee benefit plan&#146;s
annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934)
that is incorporated by reference in the Registration Statement shall be deemed
to be a new Registration Statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the
initial <I>bona fide</I> offering thereof. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may
be permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been
advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act of
1933 and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities
Act of 1933 and will be governed by the final adjudication of such issue. </FONT></P>

<P ALIGN=CENTER><FONT SIZE=3><B>SIGNATURES</B></FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that
it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of San
Diego, State of California, on December 21, 2000. </FONT></P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=50% ALIGN=LEFT><BR>
<BR>
Date: December 21, 2000
 </TD>
<TD WIDTH=50% ALIGN=LEFT><B>ALLIANCE PHARMACEUTICAL CORP.</B><BR>
(Registrant)<BR>
<BR>
By: <U>/s/ Theodore D. Roth</U><BR>
Theodore D. Roth<BR>
President and Chief Operating Officer
</TD>
</TR>
</TABLE>


<P ALIGN=CENTER><B> POWER OF ATTORNEY</B></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below
constitutes and appoints Duane J. Roth and Theodore D. Roth, or either of them,
his true and lawful attorney-in-fact and agent, with full power of substitution
and resubstitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all amendments to this Registration Statement, and
to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the
premises, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact, agent,
or their substitutes may lawfully do or cause to be done by virtue hereof. </FONT></P>

<P><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement
has been signed by the following persons in the capacities and on the dates
indicated.</B> </FONT></P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U><B>Signature</B></U></TD>
<TD WIDTH=34% ALIGN=LEFT><U><B>Title</B></U></TD>
<TD WIDTH=33% ALIGN=LEFT><U><B>Date</B></U></TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Duane J. Roth</U><BR>
                         Duane J. Roth
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Chairman and Chief Executive Officer</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Theodore D. Roth</U><BR>
                         Theodore D. Roth </TD>
<TD WIDTH=34% ALIGN=LEFT>Director, President and Chief<BR>
                         Operating Officer</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000  </TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Tim T. Hart</U><BR>
                         Tim T. Hart
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Chief Financial Officer, Treasurer<BR>
                         and Chief Accounting Officer
                         </TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Pedro Cuatrecasas, M.D.</U><BR>
                         Pedro Cuatrecasas, M.D.
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Director</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Fred M. Hershenson, Ph.D.</U><BR>
                         Fred M. Hershenson, Ph.D.
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Director</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Carroll O. Johnson</U><BR>
                         Carroll O. Johnson</TD>
<TD WIDTH=34% ALIGN=LEFT> Director</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Stephen M. McGrath</U><BR>
                         Stephen M. McGrath</TD>
<TD WIDTH=34% ALIGN=LEFT>Director</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Helen M. Ranney, M.D.</U><BR>
                         Helen M. Ranney, M.D.
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Director </TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Thomas F. Zuck, M.D.</U><BR>
                         Thomas F. Zuck, M.D.
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Director</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000</TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Donald E. O'Neill</U><BR>
                         Donald E. O'Neill
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Director</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000 </TD>
</TR>
</TABLE>
<BR>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=33% ALIGN=LEFT><U>/s/ Jean G. Riess, Ph.D.</U><BR>
                         Jean G. Riess, Ph.D.
                         </TD>
<TD WIDTH=34% ALIGN=LEFT>Director</TD>
<TD WIDTH=33% ALIGN=LEFT>December 21, 2000 </TD>
</TR>
</TABLE>
<BR>

</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "0001.htm", "secsgml_size_bytes": 21935}]
{"company-data": {"conformed-name": "ALLIANCE PHARMACEUTICAL CORP", "cik": "0000736994", "assigned-sic": "2835", "irs-number": "141644018", "state-of-incorporation": "NY", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-52432", "film-number": "793404"}, "business-address": {"street1": "6175 LUSK BLVD", "city": "SAN DIEGO", "state": "CA", "zip": "92121", "phone": "8584105200"}, "mail-address": {"street1": "617 LUSK BLVD", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}, "former-company": [{"former-conformed-name": "OTISVILLE BIOPHARM INC", "date-changed": "19890310"}, {"former-conformed-name": "OTISVILLE BIOTECH INC", "date-changed": "19861216"}]}
S-8
As filed with the Securities and Exchange Commission on December 21,
2000
Registration Statement No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
ALLIANCE PHARMACEUTICAL CORP.
(Exact name of registrant as specified in its charter)
New York
(State or other jurisdiction
of incorporation or organization)
14-1644018
(I.R.S. Employer
Identification Number)
3040 Science Park Road
San Diego, CA 92121
(858) 410-5200
(Address,
including zip code, and telephone number, including area code of
registrant's principal executive offices)
2000 STOCK OPTION PLAN OF ALLIANCE PHARMACEUTICAL CORP.
(Full title of the plan)
DUANE J. ROTH
Chief Executive Officer
Alliance Pharmaceutical Corp.
3040 Science Park Road
San Diego, CA 92121
(858)410-5200
(Name, address, including zip code, and telephone number, of agent
for service of process)
Copy to:
Melvin Epstein, Esq.
Stroock & Stroock & Lavan LLP
180 Maiden Lane
New York, NY 10038
CALCULATION OF REGISTRATION FEE
---------------------------------------------------------------------------------------------------------------------------
                                                    Proposed Maximum      Proposed Maximum Aggregate   Amount of
 Title of Shares             Amount to be           Aggregate Price       Offering Price               Registration Fee
 to be Registered            Registered             Per Unit (1)
---------------------------------------------------------------------------------------------------------------------------
 Common Stock, $.01 par
         value.              2,100,000 shares (2)     $8.19 per share      $17,199,000                 $4,540.54
---------------------------------------------------------------------------------------------------------------------------

(1) Estimated solely for the purpose of calculating the registration fee
    pursuant to Rule 457(c) and (h) of the Securities Act of 1933, as amended, based
    on the average of the high and low prices of the common stock on the Nasdaq
    National Market on December 19, 2000.

(2) Pursuant to Rule 416(a) under the Securities Act of 1933, this Registration
    Statement also covers an indeterminate number of shares of Common Stock which
    may be issued by reason of stock splits, stock dividends or similar
    transactions.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The
documents containing the information specified in Part I of Form S-8 will be
sent or given to employees as specified by Rule 428(b)(1) promulgated under the
Securities Act of 1933, as amended (the "Securities Act"). Such
documents need not be filed with the Securities and Exchange Commission (the
"Commission") either as part of this Registration Statement or as
prospectuses or prospectus supplements pursuant to Rule 424 under the Securities
Act. These documents and the documents incorporated by reference in the
Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken
together, constitute a prospectus that meets the requirements of Section 10(a)
of the Securities Act. See Rule 428(a)(1) under the Securities Act.
This
Registration Statement covers 2,100,000 shares of Alliance Pharmaceutical Corp.
(the "Registrant") Common Stock, $.01 par value (plus any additional
shares of Common Stock that may be issued by reason of stock splits, stock
dividends or similar transactions), to be issued pursuant to the
Registrant's 2000 Stock Option Plan.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The
following documents filed by the Registrant with the Securities and Exchange
Commission (the "Commission") are incorporated herein by reference:
(a)
     The Registrant's Annual Report on Form 10-K for
the fiscal year ended June 30, 2000;
(b)      The
Registrant's Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2000;
nbsp;      (c)
     All other reports filed by the Registrant pursuant to Sections 13(a) and 15(d)
of the Exchange Act since the fiscal year covered by the annual report referred
to in (a) above; and
(d)
     The description of the Registrant's Common Stock, $.01 par value, which is
contained in the Registrant's Registration Statement on Form 8-A,
declared effective October 25, 1984, filed with the Commission to register such
Common Stock pursuant to Section 12(b) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act").
All
documents subsequently filed by the Registrant pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective
amendment which indicates that all securities offered hereby have been sold or
which deregisters all securities then remaining unsold, shall be deemed to be
incorporated by reference herein and to be a part hereof from the date of filing
of such documents.
Any
statement contained herein or in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Registration Statement to the extent that a statement
contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference herein modifies or supersedes such
statement. Any statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this Registration
Statement.
Item 4.
Description of Securities.
Not
Applicable.
Item 5.
Interests of Named Experts and Counsel
.
Not
Applicable.
Item 6.
Indemnification of Directors and Officers
.
The
Certificate of Incorporation and By-laws of the Registrant provide for the
Registrant to indemnify its officers, directors and employees to the fullest
extent permitted by the New York Corporation Law against certain liabilities and
expenses.
Item 7.
Exemption From Registration Claimed
.
Not
Applicable.
Item 8.
Exhibits
.
Exhibit
Number
Description
4.1
Option Plan
4.2
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 of
the Registrant's Form S-2 dated April 19, 1989).
5
Opinion of Stroock & Stroock & Lavan LLP.
23.1
Consent of Stroock & Stroock & Lavan LLP (included in Exhibit 5 hereto).
23.2
Consent of Ernst & Young LLP, Independent Auditors.
24
Power of Attorney (included as part of the signature page of this Registration
Statement).
Item 9.
Undertakings
.
The undersigned
Registrant hereby undertakes:
(1)
     To file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of
1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective
date of the Registration Statement (or the most recent post- effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the Registration Statement;
(iii)
To include any material information with respect to the plan of distribution not
previously disclosed in the Registration Statement or any material change to
such information in the Registration Statement;
provided, however
,
that paragraphs (1)(i) and (1)(ii) do not apply if the Registration Statement is
on Form S-3 or Form S-8 and the information required to be included in a
post-effective amendment by those paragraphs is contained in periodic reports
filed with or furnished to the Commission by the Registrant pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by
reference in the Registration Statement.
(2)
     That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new Registration Statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial
bona fide
offering thereof.
(3)
     To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the
offering.
(4)
     If the Registrant is a foreign private issuer, to file a post-effective
amendment to the Registration Statement to include any financial statements
required by Rule 3-19 of Regulation S-X at the start of any delayed offering or
throughout a continuous offering.
The
undersigned Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the Registrant's
annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act
of 1934 (and, where applicable, each filing of an employee benefit plan's
annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934)
that is incorporated by reference in the Registration Statement shall be deemed
to be a new Registration Statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the
initial
bona fide
offering thereof.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may
be permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been
advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act of
1933 and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities
Act of 1933 and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that
it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of San
Diego, State of California, on December 21, 2000.
Date: December 21, 2000
ALLIANCE PHARMACEUTICAL CORP.
(Registrant)
By:
/s/ Theodore D. Roth
Theodore D. Roth
President and Chief Operating Officer
POWER OF ATTORNEY
KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below
constitutes and appoints Duane J. Roth and Theodore D. Roth, or either of them,
his true and lawful attorney-in-fact and agent, with full power of substitution
and resubstitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all amendments to this Registration Statement, and
to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the
premises, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact, agent,
or their substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement
has been signed by the following persons in the capacities and on the dates
indicated.
Signature
Title
Date
/s/ Duane J. Roth
Duane J. Roth
Chairman and Chief Executive Officer
December 21, 2000
/s/ Theodore D. Roth
Theodore D. Roth
Director, President and Chief
Operating Officer
December 21, 2000
/s/ Tim T. Hart
Tim T. Hart
Chief Financial Officer, Treasurer
and Chief Accounting Officer
December 21, 2000
/s/ Pedro Cuatrecasas, M.D.
Pedro Cuatrecasas, M.D.
Director
December 21, 2000
/s/ Fred M. Hershenson, Ph.D.
Fred M. Hershenson, Ph.D.
Director
December 21, 2000
/s/ Carroll O. Johnson
Carroll O. Johnson
Director
December 21, 2000
/s/ Stephen M. McGrath
Stephen M. McGrath
Director
December 21, 2000
/s/ Helen M. Ranney, M.D.
Helen M. Ranney, M.D.
Director
December 21, 2000
/s/ Thomas F. Zuck, M.D.
Thomas F. Zuck, M.D.
Director
December 21, 2000
/s/ Donald E. O'Neill
Donald E. O'Neill
Director
December 21, 2000
/s/ Jean G. Riess, Ph.D.
Jean G. Riess, Ph.D.
Director
December 21, 2000